Rxilient

What Rxilient does

Rxilient is a Singapore-headquartered pharmaceutical Contract Development and Manufacturing Organization (CDMO) founded in 2019 and operating with 11 to 50 employees. The company provides CDMO services to pharmaceutical clients, encompassing drug substance development, formulation, and contract manufacturing support typical of regional CDMOs at this scale. Its private, for-profit status and Singapore domicile position it within a recognized regional pharmaceutical hub with established GMP infrastructure and clear bilateral regulatory recognition (US FDA, EMA, HSA), making it a plausible gateway for serving Southeast Asian and broader Asia-Pacific pharmaceutical customers.

The company's go-to-market is built around its CDMO service offering, with revenue mechanics tied to development fees, milestone payments, and commercial manufacturing contracts — the standard monetization model for early- to mid-stage CDMOs. No specific pricing model, customer logos, distribution channels, or detailed product/service breakdowns are disclosed in the available sources; the corporate website returns only a loading/verification page and does not surface substantive company information. As a result, segment focus, customer mix, and contract value ranges cannot be quantified from public material.

In October 2023, Rxilient closed a $30 million funding round led by Pharmaron — a leading global pharmaceutical services and CDMO platform — with participation from Legend Capital. The presence of Pharmaron as lead investor is the most strategically informative signal in the dataset: it ties Rxilient into the orbit of a top-tier global CDMO and likely provides access to technical know-how, capacity, and potentially cross-referral of clients. Given the four-year operating history, sub-50 headcount, and recent sizable raise, the company appears to be in a scale-up phase, deploying capital toward capacity build-out, geographic expansion, or service-line broadening rather than operating as a mature commercial manufacturer.

Name

Rxilient

Website

https://rxilient.com

Company type

Private

Founded year

2019

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Pharmaceutical CDMO Services

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

akta.pro secondary industries

Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB), Small-Molecule API & Intermediates CDMO (HLAGABAA)

Keywords

• Pharmaceutical CDMO services
• Contract drug manufacturing
• Pharmaceutical development
• Contract manufacturing organization
• Drug substance manufacturing

Headquarters

HQ city

Singapore

HQ country

Singapore

HQ region

Asia

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain

Core offering

Rxilient is a pharmaceutical Contract Development and Manufacturing Organization (CDMO) that provides outsourced drug development and manufacturing services to pharmaceutical clients. Founded in 2019 and based in Singapore, the company operates with 11-50 employees to deliver contract manufacturing services in the pharmaceutical industry.

Differentiator

Problem solved

Functional benefit

Products and services

• Pharmaceutical Contract Development and Manufacturing Services Outsourced pharmaceutical drug development and manufacturing services provided to pharmaceutical company clients on a contract basis.

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves3 records

Expansion highlights3 records

Direct peers

• Asymchem Laboratories: Asymchem is a leading China-based CDMO specializing in small-molecule API and intermediates with growing drug product capabilities. It targets similar innovator and generic pharma customers in APAC and globally.
• Pharmaron: Pharmaron is a global integrated CDMO offering drug discovery, development, and manufacturing services across APIs and drug product. It is the lead investor in Rxilient and operates in the same integrated pharmaceutical CDMO space, making it the closest comparable despite its scale advantage.
• WuXi STA: WuXi STA is one of the largest integrated CDMOs globally, offering both small-molecule API and drug product services. It directly competes for the same APAC-based pharmaceutical outsourcing programs that Rxilient targets.
• Cambrex: Cambrex is a US-based small-molecule API and finished dosage CDMO serving innovator and generic pharma customers. It is a direct functional comparable to Rxilient across drug substance and drug product integrated offerings.
• Alcami Corporation: Alcami is a US-based CDMO offering integrated drug substance and drug product services for small molecules and biologics. It is a comparable integrated-pharma CDMO competing for similar mid-sized pharma outsourcing programs.

Regional players

• Samsung Biologics: Samsung Biologics is a leading Asia-based biologics CDMO headquartered in South Korea. While primarily biologics-focused, it competes for integrated CDMO mandates across APAC and represents the regional supply density Rxilient faces.

Broad incumbents

• Catalent: Catalent is a major global CDMO with deep expertise in drug product formulation, softgel, and biologics. It represents the type of incumbent Rxilient must differentiate against for integrated development and manufacturing programs.
• Lonza Group: Lonza is the world's largest CDMO across small molecules, biologics, and cell & gene therapies. It sets the competitive benchmark Rxilient must meet on GMP certification, regulatory track record, and global commercial supply capability.
• Recipharm: Recipharm is a European-headquartered CDMO with broad small-molecule drug product capabilities. It serves similar innovator and generic pharma customers for outsourced development and commercial manufacturing.
• Siegfried Holding: Siegfried is a Swiss-listed integrated CDMO covering APIs and finished dosage forms. It is comparable to Rxilient in target market and service breadth, though at significantly greater scale.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights4 records

Customer concentration

• LinkedInlinkedin.com/company/rxilient-health

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Rxilient